Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/682593
Kazakhstan Pharmaceuticals and Healthcare Report Q4 2008
Description:
Kazakhstan Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Kazakhstan's pharmaceuticals and healthcare industry.
Kazakhstan’s pharmaceutical market has emerged as one of the more promising prospects within the Emerging Europe region. In the BMI Business Environment Ranking matrix for Q408, Kazakhstan moved up from 15 (out of 17 markets surveyed in the region) to joint 11th position, alongside the more established market of Slovakia. While the country is disadvantaged by low per capita spend on medicine and the lack of universal reimbursement, the forecast growth of its pharmaceutical market (at a CAGR of over 1935% in US dollar terms) makes for a very attractive proposition.
The above view is supported by the recently published data by the Kazakhstan Pharmaceutical Herald, which show that retail sales grew by 33% year-on-year (y-o-y) in H108 to US$388.3mn. In the same period, volume of packs sold rose by 43% to 252.5mn. While the figures are above BMI’s estimates, our calculations are reinforced by sales data from the Association of International Pharmaceutical Manufacturers in Russia (AIPM) and Research Marketing & Business Consulting Company (RMBC). AIPM/RMBC figures showed hospital sales increasing 18% y-o-y in Q108, while retail sales increased 17%, suggesting a possible slowdown in the latter segment.
The top three drugs by sales reported by the Kazakhstan Pharmaceutical Herald were Nycomed’s Actovegin (deproteinised calf blood derivative), Novartis’ over-the-counter (OTC) flu treatment Theraflu (acetaminophen + chlorpheniramine + dextromethorphan + phenylephrine + pheniramine + diphenhydramine + guaifenesin) and Berlin-Chemie/Menarini’s Mezim forte (mixture of digestive enzymes). The above information is indicative of the import-dependent market, with the domestic industry only meeting 10% of the local demand, as well as the high market penetration of OTCs, in the absence of a comprehensive reimbursement system.
The high cost of healthcare system modernisation will continue to drive the development of the OTC market, as the government seeks measures for containing healthcare as well as pharmaceutical costs. Given that hospitals remain a key point of access for much of the population, the government’s recently announced creation of a centralised system for drug distribution comes as no surprise. The new system, due to cover up to 80% of all drugs supplied to hospitals, will mean that a single company will reap considerable benefits in terms of volume, although values are likely to suffer in the face of anticipated lower tendering prices.
Kazakhstan’s pharmaceutical market has emerged as one of the more promising prospects within the Emerging Europe region. In the BMI Business Environment Ranking matrix for Q408, Kazakhstan moved up from 15 (out of 17 markets surveyed in the region) to joint 11th position, alongside the more established market of Slovakia. While the country is disadvantaged by low per capita spend on medicine and the lack of universal reimbursement, the forecast growth of its pharmaceutical market (at a CAGR of over 1935% in US dollar terms) makes for a very attractive proposition.
The above view is supported by the recently published data by the Kazakhstan Pharmaceutical Herald, which show that retail sales grew by 33% year-on-year (y-o-y) in H108 to US$388.3mn. In the same period, volume of packs sold rose by 43% to 252.5mn. While the figures are above BMI’s estimates, our calculations are reinforced by sales data from the Association of International Pharmaceutical Manufacturers in Russia (AIPM) and Research Marketing & Business Consulting Company (RMBC). AIPM/RMBC figures showed hospital sales increasing 18% y-o-y in Q108, while retail sales increased 17%, suggesting a possible slowdown in the latter segment.
The top three drugs by sales reported by the Kazakhstan Pharmaceutical Herald were Nycomed’s Actovegin (deproteinised calf blood derivative), Novartis’ over-the-counter (OTC) flu treatment Theraflu (acetaminophen + chlorpheniramine + dextromethorphan + phenylephrine + pheniramine + diphenhydramine + guaifenesin) and Berlin-Chemie/Menarini’s Mezim forte (mixture of digestive enzymes). The above information is indicative of the import-dependent market, with the domestic industry only meeting 10% of the local demand, as well as the high market penetration of OTCs, in the absence of a comprehensive reimbursement system.
The high cost of healthcare system modernisation will continue to drive the development of the OTC market, as the government seeks measures for containing healthcare as well as pharmaceutical costs. Given that hospitals remain a key point of access for much of the population, the government’s recently announced creation of a centralised system for drug distribution comes as no surprise. The new system, due to cover up to 80% of all drugs supplied to hospitals, will mean that a single company will reap considerable benefits in terms of volume, although values are likely to suffer in the face of anticipated lower tendering prices.
Contents:
Executive Summary
Kazakhstan Pharmaceuticals And Healthcare SWOT
Kazakhstan Political SWOT
Kazakhstan Economic SWOT
Kazakhstan – Business Environment Ranking
Table: Central And Eastern Europe Pharmaceutical And Healthcare Business Environment Rankings
Limits Of Potential Returns
Risks To Realisation Of Returns
Kazakhstan – Market Summary
Regulatory Regime
Intellectual Property Environment
Counterfeit Drugs
Pricing And Reimbursement Regime
Table: Price Components And Add-Ons For Imported And Locally Produced Generic Medicines (KZT)
Recent Pricing And Reimbursement Developments
Industry Developments
Epidemiology
Healthcare Sector
Table: Top 10 Manufacturers By Value Of Hospital Purchases
Table: Top 10 INNs by Value of Hospital Purchases
Healthcare Sector Financing
Table: Top 10 ATC Groups by Value of Hospital Purchases
Table: Top 10 ATC Groups by Retail Pharmacy Sales
Domestic Pharmaceutical Industry
Recent Domestic Industry Developments
Wholesale And Retail
Recent Wholesale And Retail Developments
Foreign Pharmaceutical Industry
Table: Indo-Kazakh Trade Figures, 1999-2003 (US$mn)
Recent Foreign Industry Developments
Table: Pharmaniaga’s Key Products
Medical Devices
Table Medical Devices Market In Kazakhstan, 2003-2005 (US$mn)
Industry Forecast Scenario
Overall Market Forecast
Table: Kazakhstan’s Drug Expenditure Indicators, 2004-2012
Key Growth Factors – Industry
Table: Kazakhstan’s Health Expenditure Indicators, 2004-2012
Key Growth Factors – Macroeconomic
Table: Kazakhstan – Macroeconomic Activity, 2005-2012
Prescription Market Forecast
Table: Kazakhstan’s Prescription Market Indicators, 2004-2012 (KZTmn unless otherwise stated)
OTC Market Forecast
Table: Kazakhstan’s OTC Market Indicators, 2004-2012 (KZTmn unless otherwise stated)
Patented Market Forecast
Table: Kazakhstan’s Patented Drug Market Indicators, 2004-2012
Generics Market Forecast
Table: Kazakhstan’s Generics Market Indicators, 2004-2012 (KZTmn unless otherwise stated)
Export/Import Market Forecasts
Table: Kazakhstan’s Pharmaceutical Trade Indicators, 2004-2012 (US$mn unless otherwise stated)
Table Retail Sales Structure Of Imports By Pharmaceutical Subgroups, 2006
Table: Top 15 Distributors By Value Importing Pharmaceuticals Into Kazakhstan, 2006
Table: Top 15 Distributors By Volume Importing Pharmaceuticals Into Kazakhstan, 2006
Other Healthcare Data Forecasts
Table: Kazakhstan’s Other Healthcare Data, 2004-2012
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Table: Top 10 Manufacturers By Retail Pharmacy Sales
Table: Top 10 Trade Names by Value of Retail Pharmacy Sales
Company Monitor
Foreign Companies
- Novartis (Sandoz)
- Sanofi-Aventis
- GlaxoSmithKline (GSK)
- Nycomed
- Merck & Co
- Pfizer
- Ranbaxy
Indigenous Companies
- Chimpharm
- Romat FK
Country Snapshot: Kazakhstan Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 1999-2004
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Kazakhstan Pharmaceuticals And Healthcare SWOT
Kazakhstan Political SWOT
Kazakhstan Economic SWOT
Kazakhstan – Business Environment Ranking
Table: Central And Eastern Europe Pharmaceutical And Healthcare Business Environment Rankings
Limits Of Potential Returns
Risks To Realisation Of Returns
Kazakhstan – Market Summary
Regulatory Regime
Intellectual Property Environment
Counterfeit Drugs
Pricing And Reimbursement Regime
Table: Price Components And Add-Ons For Imported And Locally Produced Generic Medicines (KZT)
Recent Pricing And Reimbursement Developments
Industry Developments
Epidemiology
Healthcare Sector
Table: Top 10 Manufacturers By Value Of Hospital Purchases
Table: Top 10 INNs by Value of Hospital Purchases
Healthcare Sector Financing
Table: Top 10 ATC Groups by Value of Hospital Purchases
Table: Top 10 ATC Groups by Retail Pharmacy Sales
Domestic Pharmaceutical Industry
Recent Domestic Industry Developments
Wholesale And Retail
Recent Wholesale And Retail Developments
Foreign Pharmaceutical Industry
Table: Indo-Kazakh Trade Figures, 1999-2003 (US$mn)
Recent Foreign Industry Developments
Table: Pharmaniaga’s Key Products
Medical Devices
Table Medical Devices Market In Kazakhstan, 2003-2005 (US$mn)
Industry Forecast Scenario
Overall Market Forecast
Table: Kazakhstan’s Drug Expenditure Indicators, 2004-2012
Key Growth Factors – Industry
Table: Kazakhstan’s Health Expenditure Indicators, 2004-2012
Key Growth Factors – Macroeconomic
Table: Kazakhstan – Macroeconomic Activity, 2005-2012
Prescription Market Forecast
Table: Kazakhstan’s Prescription Market Indicators, 2004-2012 (KZTmn unless otherwise stated)
OTC Market Forecast
Table: Kazakhstan’s OTC Market Indicators, 2004-2012 (KZTmn unless otherwise stated)
Patented Market Forecast
Table: Kazakhstan’s Patented Drug Market Indicators, 2004-2012
Generics Market Forecast
Table: Kazakhstan’s Generics Market Indicators, 2004-2012 (KZTmn unless otherwise stated)
Export/Import Market Forecasts
Table: Kazakhstan’s Pharmaceutical Trade Indicators, 2004-2012 (US$mn unless otherwise stated)
Table Retail Sales Structure Of Imports By Pharmaceutical Subgroups, 2006
Table: Top 15 Distributors By Value Importing Pharmaceuticals Into Kazakhstan, 2006
Table: Top 15 Distributors By Volume Importing Pharmaceuticals Into Kazakhstan, 2006
Other Healthcare Data Forecasts
Table: Kazakhstan’s Other Healthcare Data, 2004-2012
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Table: Top 10 Manufacturers By Retail Pharmacy Sales
Table: Top 10 Trade Names by Value of Retail Pharmacy Sales
Company Monitor
Foreign Companies
- Novartis (Sandoz)
- Sanofi-Aventis
- GlaxoSmithKline (GSK)
- Nycomed
- Merck & Co
- Pfizer
- Ranbaxy
Indigenous Companies
- Chimpharm
- Romat FK
Country Snapshot: Kazakhstan Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 1999-2004
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Companies Mentioned
- Novartis (Sandoz)
- Sanofi-Aventis
- GlaxoSmithKline (GSK)
- Nycomed
- Merck & Co
- Pfizer
- Ranbaxy
- Chimpharm
- Romat FK
- Sanofi-Aventis
- GlaxoSmithKline (GSK)
- Nycomed
- Merck & Co
- Pfizer
- Ranbaxy
- Chimpharm
- Romat FK
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Friday, May 24, 2013
5:43:32 AM
5:43:32 AM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Kazakhstan Pharmaceuticals and Healthcare Report Q4 2008
Web Address
http://www.researchandmarkets.com/reports/682593
Office Code
OC8DIQSNROWSXT
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Electronic (PDF) - Single User |
|
EURO€ 874.00 |
|---|
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Friday, May 24, 2013
5:43:32 AM
5:43:32 AM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp